Sipuleucel-T (known by the trade name, "Provenge") is the first prostate cancer vaccine approved by the Food and Drug Administration (FDA), and represents a new type of cancer therapy termed, Autologous Cellular Immunotherapy (ACT). This therapy has been described as a revolution in technology by clinicians and researchers alike. However, policy-makers and health economists question the efficacy of such treatment given its costs, while mainstream media often bemoan Provenge as yet another example of a healthcare system gone awry. This paper examines the debate for and against Provenge, and discusses why Medicare adoption of payment protocols for the vaccine may violate the egalitarian and feminist principles of distributive justice theory. The paper also acknowledges the larger context of the Provenge debate within the bioethical community; that is, how much should society be willing to invest to prevent death? The paper concludes by arguing for a more thorough ethical review of such new technologies by policy-makers prior to the adoption of funding protocols.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4161/hv.7.4.14189 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Coley's Toxin to First Approved Therapeutic Vaccine-A Brief Historical Account in the Progression of Immunobiology-Based Cancer Treatment.
Biomedicines
November 2024
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cancer immunobiology is one of the hot topics of discussion amongst researchers today, and immunotherapeutic modalities are among the selected few emerging approaches to cancer treatment that have exhibited a promising outlook. However, immunotherapy is not a new kid on the block; it has been around for centuries. The origin of cancer immunotherapy in modern medicine can be traced back to the initial reports of spontaneous regression of malignant tumors in some patients following an acute febrile infection, at the turn of the twentieth century.
View Article and Find Full Text PDFMedication Prescription Policy for US Veterans With Metastatic Castration-Resistant Prostate Cancer: Causal Machine Learning Approach.
JMIR Med Inform
November 2024
School of Medicine, Saint Louis University, St. Louis, MO, United States.
Article Synopsis
- - Prostate cancer is the second leading cause of death in American men, but early detection and treatment can be curative; advanced stages like mCRPC pose significant mortality risks.
- - This study examined how different medications (abiraterone and enzalutamide) affect the survival duration of patients with mCRPC, using machine learning to analyze patient demographics and health data.
- - Findings revealed that veterans treated with enzalutamide had an average increase of approximately 60 days in survival compared to those treated with abiraterone, highlighting the potential for tailored treatment strategies.
Seeing the Future of Lung Cancer Vaccination.
Int J Mol Sci
October 2024
Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
It has been nearly fifteen years since the Food and Drug Administration (FDA) approved the first therapeutic cancer vaccine for solid tumors, namely Sipuleucel-T (Provenge), marking a significant milestone in the treatment of metastatic castration-resistant prostate cancer [...
View Article and Find Full Text PDFBone-Targeting Radionuclides in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review on Radium-223 Chloride (Alpharadin) in Combination with Other Therapies.
Diagnostics (Basel)
October 2024
Department of Radiological Sciences, Faculty of Applied Medical Sciences, Najran University, Najran 61441, Saudi Arabia.
Recent advances have broadened the range of therapeutic options for mCRPC, with several new treatments, including novel hormonal therapies (enzalutamide, abiraterone), chemotherapeutic agents (docetaxel, cabazitaxel), immunotherapies (sipuleucel-T), and bone targeting radiopharmaceuticals (radium-223) showing improved clinical outcomes and receiving U.S. Food and Drug Administration approval.
View Article and Find Full Text PDFProstate Cancer, Pathophysiology and Recent Developments in Management: A Narrative Review.
Curr Oncol Rep
November 2024
Department of Basic and Clinical Sciences, University of Nicosia Medical School, 21 Ilia Papakyriakou, 2414 Engomi, P.O. Box 24005, 1700, Nicosia, Cyprus.
Article Synopsis
- Prostate cancer is the second most common cancer in men, with various stages ranging from localized to metastatic disease, and treatment for advanced stages typically involves external beam radiotherapy and hormonal therapy for better prognosis.
- Current therapies for non-metastatic castration-resistant prostate cancer (M0 CRPCa) utilize androgen deprivation combined with new drugs, showing promising results in clinical trials for prolonging metastatic-free survival.
- New drug developments, including PARP inhibitors and Lutetium-177, along with ongoing clinical trials for treatments like cabozantinib and CAR T-cell therapy, aim to improve overall survival rates and slow disease progression in advanced prostate cancer cases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!